Rhythm Pharmaceuticals
$18.679876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.11 (+0.57%) As of 1:45 PM EST today
+$0.11 (+0.57%) Today
Why Robinhood?
You can buy or sell RYTM and other stocks, options, ETFs, and crypto commission-free!
About RYTM
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Read More The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
Employees
54
Headquarters
Boston, Massachusetts
Founded
2010
Market Cap
784.96M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
152.45K
High Today
$18.85
Low Today
$18.30
Open Price
$18.54
Volume
71.32K
52 Week High
$31.94
52 Week Low
$17.26
Collections
Analyst Ratings
88%
of 8 ratings
Buy
88%
Hold
0%
Sell
13%
RYTM Earnings
-$1.24
-$0.83
-$0.41
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
— per share
Actual
Expected Mar 6, Pre-Market
People Also Bought
uniQure
675
$62.20
-2.19%Viking Therapeutics
38,948
$6.88
-1.15%Global Blood Therapeutics
1,130
$73.84
+1.01%Canopy Growth
178,882
$21.99
-1.43%Cloudera
13,438
$10.86
-1.85%Voyager Therapeutics
1,177
$12.66
-0.63%CRISPR
26,926
$53.83
-5.16%Abeona Therapeutics
2,309
$4.13
+2.74%Teladoc Health
10,781
$113.43
-2.14%Sarepta Therapeutics
2,065
$123.87
+0.63%TG Therapeutics
5,252
$15.54
-1.80%Amarin
16,336